Cubist Is Latest Heptares Collaborator On GPCR-Targeted Drugs
This article was originally published in The Pink Sheet Daily
U.S. acute hospital care specialist Cubist has become the sixth major pharma company to collaborate with U.K.-based Heptares on finding novel therapeutics that interact with G-protein coupled receptors.
You may also be interested in...
The U.K.'s G-protein coupled receptor specialist, Heptares, could receive up to $190 million plus royalties from Shire as it concludes its first product out-licensing agreement.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.